- Home
- JG vs AVTX Comparison
JG vs AVTX Comparison
Compare JG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JG
- AVTX
- Stock Information
- Founded
- JG 2012
- AVTX 2011
- Country
- JG China
- AVTX United States
- Employees
- JG 393
- AVTX N/A
- Industry
- JG Computer Software: Programming Data Processing
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- JG Technology
- AVTX Health Care
- Exchange
- JG Nasdaq
- AVTX Nasdaq
- Market Cap
- JG 52.8M
- AVTX 57.4M
- IPO Year
- JG 2018
- AVTX 2015
- Fundamental
- Price
- JG $8.85
- AVTX $4.20
- Analyst Decision
- JG
- AVTX Strong Buy
- Analyst Count
- JG 0
- AVTX 6
- Target Price
- JG N/A
- AVTX $34.20
- AVG Volume (30 Days)
- JG 14.1K
- AVTX 67.7K
- Earning Date
- JG 06-05-2025
- AVTX 05-20-2025
- Dividend Yield
- JG N/A
- AVTX N/A
- EPS Growth
- JG N/A
- AVTX N/A
- EPS
- JG N/A
- AVTX N/A
- Revenue
- JG $43,316,299.00
- AVTX $441,000.00
- Revenue This Year
- JG $10.90
- AVTX N/A
- Revenue Next Year
- JG N/A
- AVTX N/A
- P/E Ratio
- JG N/A
- AVTX N/A
- Revenue Growth
- JG 8.94
- AVTX N/A
- 52 Week Low
- JG $2.36
- AVTX $4.15
- 52 Week High
- JG $20.94
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- JG 48.85
- AVTX 31.45
- Support Level
- JG $8.45
- AVTX $4.27
- Resistance Level
- JG $9.35
- AVTX $5.26
- Average True Range (ATR)
- JG 0.33
- AVTX 0.43
- MACD
- JG 0.10
- AVTX 0.04
- Stochastic Oscillator
- JG 58.06
- AVTX 1.25
About JG Aurora Mobile Limited
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).